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A strong connection between neuronal and metabolic health has been revealed in recent years. It appears that both normal and
pathophysiological aging, as well as neurodegenerative disorders, are all profoundly inﬂuenced by this “neurometabolic” interface,
that is, communication between the brain and metabolic organs. An important aspect of this “neurometabolic” axis that needs
to be investigated involves an elucidation of molecular factors that knit these two functional signaling domains, neuronal and
metabolic, together. This paper attempts to identify and discuss a potential keystone signaling factor in this “neurometabolic”
axis, that is, the epidermal growth factor receptor (EGFR). The EGFR has been previously demonstrated to act as a signaling
nexus for many ligand signaling modalities and cellular stressors, for example, radiation and oxidative radicals, linked to aging and
degeneration. The EGFR is expressed in a wide variety of cells/tissues that pertain to the coordinated regulation of neurometabolic
activity. EGFR signaling has been highlighted directly or indirectly in a spectrum of neurometabolic conditions, for example,
metabolic syndrome, diabetes, Alzheimer’s disease, cancer, and cardiorespiratory function. Understanding the positioning of the
EGFR within the neurometabolic domain will enhance our appreciation of the ability of this receptor system to underpin highly
complex physiological paradigms such as aging and neurodegeneration.
1.Introduction
The epidermal growth factor receptor (EGFR) is a 170-
kDa single-pass transmembrane (TM) protein. The EGFR
belongs to a family of four members: erbB-1/EGFR, erbB2
(HER2/c-neu), erbB3 (Her3), and erbB4 (Her4). The basic
EGFR structure contains an immunoglobulin-like extra-
cellular ligand binding domain and an intrinsic tyrosine
(Tyr) kinase activity contained within its intracellular car-
boxyl terminal domain. Extracellular stimulating ligands,
for example, epidermal growth factor (EGF), bind to an
individual TM receptor and induce a conformational alter-
ation that causes dimerization with another ligand-bound
EGFR or with another erbB receptor. The ligand-induced
conformational changes then activate the intrinsic tyrosine
kinase domains causing subsequent autophosphorylation or
transphosphorylation of the opposing receptor in the dimer
[1, 2]. The creation of phosphorylated tyrosines then serves
to create a dynamic scaﬀolding domain for downstream
signaling molecules that possess SH2 or PTB domains, for
example, Grb2 or Shc. Not only are positive signaling
molecules recruited in this manner but also factors involved
in EGFR internalization, such as Eps15 [3], and eventual
lysosomal degradation factors, such as c-Cbl [4, 5]. Many
of the signaling functions of the EGFR are mirrored by
other members of the receptor tyrosine kinase (RTK)
receptor class, for example, ligand-induced tyrosine kinase
activation, protein scaﬀold assembly, and interaction with
multiple common downstream factors (phospholipases,
phosphoinositide kinases, non-RTKs) [6]. The commonality
of function between RTKs indicates that these receptors
are highly likely to form important, and strongly inter-
connected, links between a diverse range of physiological or
pathophysiological activities.
1.1.EGFRActivationProﬁleDiversity. The activation process
of the EGFR typically follows the generic process of EGFR
ligand stimulation, tyrosine kinase activation, dimerization2 International Journal of Endocrinology
and tyrosine (Tyr) phosphorylation, and then signaling pro-
tein complex assembly. However, there are considerable
functional nuances within this process that serve to pro-
foundly condition and add “texture” to the signaling output
from these important receptors. For example, the speciﬁc
nature of the carboxyl terminal domain phosphorylation
events provides a mechanism by which a greater variety of
signaling information can be conveyed to the intracellular
milieu. Tyr phosphorylation for EGFR may occur at various
sites including Tyr 845, 992, 1045, 1068, 1148, 1173, or
1086. Phosphorylated Tyr residues act as binding sites
for proteins containing Src-homology 2 domains (SH2)
such as Grb2, Shc and phospholipase C-gamma (PLC-γ).
Phosphorylation at Tyr 845 in the kinase domain is involved
in stabilizing the activation loop, maintaining the active
state enzyme, and providing a binding surface for substrate
proteins [7, 8]. The non-RTK c-Src is also involved in EGFR
phosphorylation at Tyr 845 [9]. The SH2 domain of PLC-
γ binds at phospho-Tyr 992, which results in activation of
PLC-γ-mediated downstream signaling [10]. A pair of phos-
phorylated EGFR residues (Tyr 1148 and Tyr 1173) provides
a docking site for the Shc scaﬀold protein, and both sites
are involved in mitogen activated protein kinase (MAPK)
signaling activation [1]. Phosphorylation of EGFR at Tyr
1045 creates a major docking site for the adapter protein
c-Cbl, leading to receptor ubiquitination and degradation
following EGFR activation [4, 5]. The multifunctional Grb2
adapter protein binds the EGFR at phospho-Tyr1068 once
the EGFR is activated [11]. Phosphorylation of the EGFR at
speciﬁc serine (Ser) and threonine residues inhibits EGFR
kinase activity. EGFR carboxy-terminal residues Ser1046 and
Ser1047 are phosphorylated by CaM kinase II; mutation
of either of these serines results in upregulated EGFR
tyrosine autophosphorylation [12]. Therefore the pattern
and timing of such EGFR posttranslational phosphorylation
events strongly aﬀect its cellular disposition and eventual
signaling capacity. Such a wide ﬂexibility of function is
typically characteristic of protein factors that are likely to
form multidimensional interactions within more complex
physiological paradigms [13, 14].
1.2. Diversity of EGFR-Stimulatory Factors. The EGFR pos-
sesses a highly complex relationship with its stimulating
ligands/factors. Endogenous peptide-based ligands that can
activate the EGFR include epidermal growth factor (EGF),
transforming growth factor (TGF)-α, amphiregulin (AR),
heparin-binding EGF (HB-EGF), betacellulin, epiregulin
(ER), and epigen [15]. The EGFR is almost unique amongst
receptor systems in that it serves as a molecular integration
site for multiple types of stimuli including: peptide ligands,
metal ions, ultraviolet and gamma radiation, osmotic shock,
membrane depolarization, and oxidative radicals [16]. This
wide range of stimuli again reinforces the concept that
the EGFR acts as a functional keystone in “higher-order”
complex systems that may underpin multifactorial global
somatic actions such as aging and metabolism.
The EGFR can be activated by small transition metal
ions such as zinc and copper (Cu) [17]. In addition to
simple metal ions, ultraviolet (UV) radiation activates the
EGFR by two ligand-binding independent mechanisms: Tyr
phosphorylation of the receptor [18–20], and via oxidative
inhibition of the RPTP-κ [21]. It appears that the generation
of reactive oxygen species (ROS) may in some cases be
secondary to EGFR activation. These ROS may lead to
the reversible inactivation of a crucial protein for EGFR
activation, that is, protein tyrosine phosphatases (PTPs) by
oxidizing the catalytic cysteine in their active site [22, 23].
Heptahelical G-protein-coupled receptors (GPCRs),
which classically were not primarily associated with
tyrosine kinase signaling cascades, have subsequently been
demonstrated to exert a profound regulatory capacity over
RTK systems, including the EGFR [24–29]. This GPCR-RTK
regulatorycapacityhasbeendemonstratedformultipletypes
of GPCRs, for example, muscarinic, bombesin, thrombin,
endothelin, lysophosphatidic acid (LPA) receptors, which
perhaps suggests that this is a common function for GPCRs
in most physiological processes. There appear to be
multiple mechanisms that can mediate this functional
GPCR-RTK interaction, however one of the most studied
involves the GPCR-induced processing of pro-HB-EGF to
its soluble form through the activation of intramembrane
metalloproteinases [30]. Matrix metalloproteinases (MMPs)
shedthepro-formoftheEGFRligandswhicharethenlocally
liberated and able to induce classical EGFR activation. It
is interesting to note that this so-called G protein-coupled
receptor RTK “transactivation” is a process not only limited
to heptahelical GPCRs. For example, the insulin-like growth
factor-1 receptor (IGF-1R), classically considered to possess
an RTK structure, is actually a “functional G protein-coupled
receptor” as it is able to stimulate guanine nucleotide
exchange event within its associated G proteins [31]. IGF-
1-mediated stimulation of the IGF-1R can therefore result
in a “transactivation” of the EGFR in a manner similar
to that induced by heptahelical GPCR activity [32]. This
interaction between the IGF-1R and the EGFR perhaps
forms one of the ﬁrst points of molecular integration
between neurological and metabolic activities. In addition
to this functional system bridge between neuronal and
metabolic systems, ligands of Gαq/11-coupled GPCRs that
are associated with insulin resistance, such as serotonin,
endothelin-1, and thrombin, may also stimulate HB-EGF
production and transactivate EGFR in 3T3-L1 adipocytes.
Serotonin has been shown to additionally have this eﬀect
in primary adipocytes and myotubes [33]. Not only can
serotonin induce activation of the EGFR but it also appears
to be able to regulate the posttranslational activity, via
serine phosphorylation and the mTOR pathway, of the
insulin/IGF-1 receptor-associated protein, IRS-1 [33]. IRS-
1 and -2 are insulin receptor-associated scaﬀold proteins
essential for eﬀectiveglucose metabolism in multiple energy-
regulatory tissues such as the liver [34]. This serotoninergic
synergy between IRS-1 phosphorylation and HB-EGF-
mediated EGFR stimulation has been demonstrated to
play a key role in serotonin-induced insulin resistance
[35]. This molecular linkage may underpin the ability of
antiserotoninergic therapy amelioration of glucose tolerance
in diabetics [36]. Insulin resistance has been shown toInternational Journal of Endocrinology 3
have causal relationships with proinﬂammatory cytokines
(including adipokines) [37], prolonged/ampliﬁed insulin
stimulation, oxidative stress, and endoplasmic reticulum
stress [38–40]. Indicating the signiﬁcant interaction of
the EGFR system with other signaling modalities, it has
been shown that activation of the growth hormone
cytokine receptor can induce phosphorylation of EGFR in
preadipocytic ﬁbroblast cell lines. This cytokine receptor-
mediated transactivation event eﬀectively modulates
EGF-induced EGFR traﬃcking and signaling [41]. It is
important to note that the growth hormone ligand and
receptor system is one of the most important factors that
controls both IGF-1 expression and secretion as well as
somatic energy metabolism.
It has been revealed in recent years that the Toll-like
receptor (TLR) system is important for neurological health
[42]. Ligand activation of multiple TLR isoforms has been
demonstrated to induce subsequent activation of EGFRs [43,
44]. This pathway involves the activation of nicotinamide
adenine dinucleotide phosphate and the generation of
reactive oxidative species (ROS). Subsequent activation of
tumor necrosis factor (TNF)-α-converting enzyme (TACE)
leads to the liberation of TGF-α from the epithelium and
productive ligation of the EGFR [45]. TLR2 activation by
lipoteichoic acid leads to a disintegrin and metalloproteinase
(ADAM)-10-induced cleavage of HB-EGF, another EGFR
ligand. Amphiregulin has also been shown to be released in
response to TNF-α [46].
It is clear therefore that in addition to its widespread
expressionandhighlytexturedsignalingactivity,theEGFRis
subject to multiple and highly diverse signaling inputs both
from other receptor systems and small molecules and ions.
These combined molecular factors and emerging evidence
of functional overlap of EGFR activities from neuronal to
metabolic systems suggest that the EGFR system may exert
a “near omnipotent” function in aging biology.
2. EGFR and the Control of
NeurometabolicPhysiology
The EGFR, and its axis of ligands demonstrate a widespread
expression proﬁle across the central nervous system (CNS)
[47]. Substantial EGFR expression is found in the neocortex
and limbic cortex, cerebellum, cerebrovascular endothelial
cells[48,49],andthemidbrain[50].EGFRhasbeendetected
in the hippocampal pyramidal cells, Purkinje cells, large
multipolar neurons of the dentate nucleus, anterior horn
cells, dorsal root ganglion cells, cells of the dorsal nucleus
of Clark, intermediolateral column cells, and ependymal
cells [51]. In the human fetal brain, EGFR has been shown
to be expressed in the subventricular zone (SVZ) [52],
hippocampus, and cerebellum [53]. This expression pattern
in the two primary areas of adult neurogenesis suggests
that the EGFR could also play a strong role in age-related
neuronal survival and regeneration. The EGFR has also
been implicated in chemotactic migration in the developing
telencephalon with implication of HB-EGF involvement
[54] .E G Fa p p e a r st oa c ta sam i t o g e nf o rn e u r a ls t e ma n d
progenitor cells (NS/NPCs) in the CNS as well as numerous
other cell types involved in neurometabolic activity. Along
with EGF, HB-EGF and TGF-α also promote proliferation
in the SVZ of an adult mouse HB-EGF [55]. In vitro,E G F
maintains NS/NPCs in the proliferative state, whereas in the
normal rodent brain, it induces proliferation and migration
in the SVZ. EGF can also increase neuronal replacement
in the ischemia-injured adult striatum. In addition, Sun et
al. (2010) found that EGF is neuroprotective rather than
neurogenic when protecting the brain from injury [56].
Notch proteins are a family of transmembrane receptor
proteins with repeated extracellular EGF and titular Notch
domains.Notchinteractswithcell-boundligands(Delta-like,
Jagged) that facilitate an inter-cellular signaling pathway that
is critical in cellular and tissue development. Notch family
members regulate developmental processes by controlling
cell fate decisions [57]. Notch and EGFR have fundamental
and selective roles in the maintenance of NS/NPCs in the
SVZ.Notchsignalingpromotesproliferativesignalingduring
neurogenesisanditsactivityisinhibitedbyNumb topromote
neural diﬀerentiation. The Numb gene product controls
binary cell fate decisions in peripheral and central nervous
systems during neurogenesis. Notch and EGFR pathway
interaction regulates neural stem cell number and self-
renewal [58]. Altering particular signaling mechanisms in
selective cell types of the SVZ can cause profound changes
in the overall cell composition of this neurogenic region
of the adult brain. Deﬁning interactions and homeostatic
mechanisms that occur between diﬀerent types of SVZ cells
under normal conditions provides crucial information on
possible alterations of speciﬁc signaling pathways that might
occur under pathological conditions or after brain injury.
The aspartyl protease, γ-secretase, is a multisubunit pro-
tease which mediates the coordinated intramembrane pro-
teolysis of both Notch and amyloid-precursor protein
(APP), which are both implicated in the etiology of
Alzheimer’s disease (AD). In some cell types the expres-
sion of EGFR and γ- s e c r e t a s eh a v eb e e nr e p o r t e dt ob e
inversely related to each other, suggesting the existence of
strong functional connection between these two systems
[59]. In a study of squamous cell carcinoma, Notch and
EGFR were shown to participate in the tumor suppressor
function of γ-secretase, again reinforcing the existence
of a physiologically-relevant EGFR-γ-secretase interaction
[60].
Given the considerable evidence for a strong role of the
EGFR in neural stem cell development it is unsurprising
that one of the functional sequelae of this activity is the
maintenanceofmemorypatternformationinthehippocam-
pus. Two of the most important regions of the CNS for
adult stem cell-mediated neurogenesis are the hippocampal
CA1 and dentate gyrus (DG) [61]. Membrane-tethered pro-
ligand, HB-EGF, is found in cells within many regions
of the CNS, for example, cerebellum, cerebral cortex as
well as the hippocampus [62]. The speciﬁc hippocampal
expression of HB-EGF and the association of the EGFR with
neurodevelopmental processes have led to the implication of
EGFR signaling insynaptic plasticity and memoryformation
[55].HB-EGFknockoutmicedemonstratealsoreducedCNS4 International Journal of Endocrinology
expression levels of neurotrophic factors including brain-
derived neurotrophic factor (BDNF), which is a ligand for
the tropomyosin-receptor kinase- (Trk-) B receptor [55].
Expression levels of BDNF and TrkB receptor activity
are both strongly correlated to the regulation of synaptic
architecture and the ability to form and retain memory
patterns. The hippocampal regions, CA1/DG, demonstrate
a tremendously high requirement for energetic support due
to their constant stimulation both from sensory inputs and
higher areas of the brain. Their huge energetic load therefore
makes CA1/DG neurons extremely sensitive to the metabolic
status of the individual [63–65].
One of the strongest points of physiological neu-
rometabolic intersection may occur via the neurometabolic
control of reproductive activity. It has been demonstrated
that there are strong gender-speciﬁc molecular mechanisms
that link hippocampal cognitive function to centrally-
controlled reproductive behavior [66–69]. It has also been
demonstrated that the EGFR is localized to the anterior pitu-
itary [70] along with EGF [71]a n dT G F - α [72], implicating
them in the reproductive hypothalamic-pituitary axis [73].
In the anterior pituitary, EGFR has been identiﬁed in lac-
tosomatotrophs [74], corticotrophs [75], and gonadotrophs
[76, 77]. The EGFR has been directly implicated in corti-
cotroph proliferation and hormone secretion, while TGF-α
has been implicated in EGFR-dependent estrogen-mediated
corticotroph cell proliferation [78, 79]. In addition to these
reproductive functions, EGFR activity is also closely associ-
ated with the dynamic regulation of prolactin transcription
and synthesis [80].
3. Role of the EGFR in
NeurometabolicPathophysiology
As one would expect from its multifactorial biological
activity, the genomic inactivation of EGFR by homologous
recombination results in profound systemic eﬀects. EGFR
genomic inactivation can induce three diﬀerent phenotypes
that range from peri-implantation lethality to postnatal
lethality [81]. EGFR-inactivated mice die at diﬀerent stages
of development depending on their genetic background;
EGFR mutant mice may die at gestation (129/Sv), at birth
(C57Bl/6), or they may live up to 8 or 20 days (CD1, MF1,
129Sv/J Swiss Black or C3H) [82–86]. After parturition,
the surviving animals may suﬀer from impaired epithelial
development in organs such as the skin, lung and gastroin-
testinal tract [83] as well as the placenta. Furthermore, there
is a strain-independent postnatal neurodegeneration in the
frontal cortex, olfactory bulb, and thalamus in surviving
EGFR-null mice [82]. This neurodegeneration is character-
ized by massive apoptosis and upregulation of c-fos [82].
The mildest form of EGFR inactivation leads to epithelial
immaturity and postnatal death due to respiratory failure
andnecrotizingenterocolitis-likelesionsintheintestine[81].
Thedefectsseeninthis“postnatallethalityphenotype”man-
ifest in the classical EGF-responsive organs (skin, intestine)
and organs undergoing branching morphogenesis during
development (lung, kidney, mammary gland, pancreas, and
prostate) and, thus, are in concordance with the concept of
EGF family members being important epithelial mitogens.
Intestinal changes observed in the EGFR-inactivated mice
diﬀer in the level of severity, the endpoint being severe
mucosal lesions and necroses (cell death) [81].
Within the CNS, it has been suggested that the EGFR
is likely to mediate the eﬀects of EGF/TGF-α on neu-
ronal diﬀerentiation [87], survival [88–90], as well as glial
proliferation [91, 92]. While many neurons of the CNS
constitutively express the EGFR [48, 49], glia and endothelial
cells demonstrate induced receptor expression following
acute injury or chronic neurodegeneration [48, 49, 93–
95]. Glial cells are vital for the generation of a dynamic
support structure for CNS activity in the face of altered
energy availability or oxidative stress [96]. TGF-α-gene
expression in glial cells is a component of the hypothalamic
response to injury [97] and it has been reported that during
development, the increased bias towards glial diﬀerentiation
is not dependent on EGFR signaling [98]. EGFR expression
appearstothecrucialfortheproliferationanddiﬀerentiation
of astrocytes [92], however, it is only one of a number
of means by which astrocytes can be induced. Burrows
et al. (1997) demonstrated that misexpression of EGFRs
promoted astrocyte development prematurely in vivo [99].
Furthermore, it was suggested that EGFRs may induce the
development of astrocytes by regulating the responses of
progenitors to various extrinsic signals such as leukemia
inhibitory factor (LIF) and bone morphogenetic proteins
(BMPs) [99]. It was also later demonstrated that EGFRs
elevate STAT3 expression and increase its phosphorylation
by LIF and that EGFRs further regulate LIF downstream of
STAT3 but they do not regulate changes in responsiveness to
BMPs [100].
Mice that do not possess EGFR develop neurodegen-
eration involving the frontal cortex and olfactory bulbs.
It has been shown that EGFR signaling controls cortical
degenerationbytheregulationofcorticalastrocyteapoptosis
[101]. Midbrain astrocytes where EGFR is absent are not
aﬀected; however, some mutant cortical astrocytes possess
an increased incidence of apoptosis which is mediated by an
Akt-caspase-dependent mechanism and these cells demon-
strate a reduced ability to support neuronal survival [101].
These results suggest two functionally distinct astrocyte
populations exist, which are diﬀerentially dependent on
EGFR signaling for their survival and also for their ability to
s u p p o r tn e u r o n a ls u r v i v a l[ 101]. These spatial diﬀerences in
astrocyte composition provide a mechanism for the region-
speciﬁc neurodegeneration in EGFR null mice [101].
TGF-α contributes to the neuroendocrine regulation of
female puberty by stimulating the release of luteinizing
hormone-releasing hormone (LHRH) [97]. It has been
proposed that TGF-α m a yb ei n v o l v e di nag l i a l - n e u r o n a l
interaction where it ﬁrst stimulates PGE2 from glial cells
which in turn elicits LHRH from neuronal terminals [102].
Interestingly astrocytes, but not LHRH neurons, express
EGFR [103]. Disruption of astroglial EGFR signaling leads
to irregular estrous cycles and a decreased secretion of LH in
female mice which eventually can cause infertility [104]. The
EGFR and TGF-α are present in the suprachiasmatic nucleusInternational Journal of Endocrinology 5
(SCN), which is the core circadian pacemaker. The SCN
releases factors acting locally within the hypothalamus, more
speciﬁcally in the neurons of the subparaventricular zone.
It has also been reported that EGFR has a circadian-time-
dependentneuromodulatoryfunctionintheSCN[105,106].
TGF-α has been implicated as an inhibitor of locomotion
and sleep-wake cycles [107]. In hamsters, these data are
conﬁrmed, and, furthermore, it was shown that central
administration of TGF-α induced weight loss [108].
4. EGFRandNeurodegenerativeDisease
AD is one of the most prevalent familial and sporadic neu-
rodegenerative disorders. One of the strongest risk factors
for AD appears to be advancing age. In addition to the
clear neurological basis of AD, the contribution of metabolic
factorstothis disorder as well as other neurological processes
hasbeenthesubjectofconsiderablerecentscrutiny[65,109–
111].InADpathology,aggregatesanddepositsoftheprotein
fragment β-amyloid (plaques) and twisted strands of the
protein Tau (neuroﬁbrillary tangles) induce the generation
of nerve cell damage and cell death in areas of the brain
including the cortex and especially the hippocampus [110,
112–114]. With respect to an association with AD etiology
it has been demonstrated that EGFR expression in the rat
brain reduces with age both in males and females [115]. AD-
related neuritic plaques observed in the cerebral cortex and
hippocampus of patients with AD also immunostain posi-
tively for EGFR [93]. In addition, it has been demonstrated
that EGFR expression is upregulated in astrocytic cells in AD
[116] and that EGFR-null astrocytes from mutant cortices in
micehaveanimpairedproliferativecapacitybothinvitroand
in vivo [82, 86]. With respect to the potential involvement of
the EGFR in the etiology neurometabolic pathophysiologies,
such as AD, a strong role for metal ion activity is likely. It has
been demonstrated that AD is often associated with a central
nervous imbalance of transition metal levels which may lead
toneurotoxicity.Transitionmetalsfacilitateoxygentransport
and its eventual usage by nervous tissue. The same metal
ion chemistry if dysregulated, for example, Cu imbalance,
can induce the generation of reactive oxygen species (ROS)
which are strongly associated with AD and pathological
aging [117]. Interestingly, clioquinol-Cu metal complexes,
which are cell-permeable, can be employed to ameliorate AD
pathologyviatheirabilitytostimulatetheEGFRinneuronal-
derived cell lines causing a reduction in β-amyloid levels
[118]. This metal ion process also appears to involve the
activation of TM matrix metalloproteinases (MMPs) as well
the nonreceptor tyrosine kinase c-Src [118]. Iron is another
metal implicated in AD through its capacity to modulate the
ability of amyloid peptides to yield ROS [119] which then
may serve to exacerbate the disorder further [120].
EGFR immunoreactivity has been localized to the brain,
pituitary, skin vascular endothelial cells of clinically diag-
nosed, pathologically conﬁrmed AD patients when samples
were collected postmortem [95]. It has also been reported
that EGFR is localized to the lumenal surface of endothelial
cells and that EGFR immunoreactivity in brain vasculature
was present in all assessed elderly patients with dementia,
when compared to nondemented patients [94]. As microvas-
cular damage and hypertension are strongly associated with
intermittent ischemia, hypoxia, and AD-related pathology, it
seems likely that the cerebrovascular activity of the EGFR
is an important aspect of its role in neurodegenerative
pathophysiology. In addition to a potential role in AD, it
has been shown that there is an increased expression of
EGFRs in the striatum in chronic Parkinsonian syndromes
but not in acute models of the disease [121]. Depletion
of neuronal dopamine is observed in Parkinson’s disease
and this subsequently would lead to decreased precursor
cell proliferation in the SVZ as well as a reduction in local
EGF production. EGFR positive cells have been reported
to be depleted in SVZ in Parkinson’s disease as well:
these data collectively indicate a role of dopamine-EGFR
signaling loop in regulation of neurogenesis of dopaminergic
neurons [122]. This process appears to involve an Wnt5a-
dopamine D2 receptor interaction in association with the
EGFR [123]. Taken together there appear to be multiple and
mechanistically diverse routes by which the EGFR may be




Aging is considered to be one of the most complex physi-
ological processes known. Despite its enormous molecular
complexity there appear to be several molecular mechanisms
in which the aging process can considered in a generic
sense, for example, disruption of hormonal axes, accu-
mulated oxidative stress, increasing nucleic acid instability,
and a reduction of metabolic eﬃciency. Even among these
common aging factors, metabolism for one appears to be
vital for all of the physiological aspects of aging. It is not
surprising therefore that many of the eﬀective antiaging
strategies intersect with this important factor [109, 124–
130]. Therefore, if metabolic function is an overarching
factor in the aging process, the question arises as to how
the multifunctional EGFR might aﬀect this profoundly
important process.
Historically, however, the EGFR has been more com-
monlyassociatedwithcancerbiologyasopposedtoneuronal
function, metabolism, or aging. Given that the EGFR is
one of the most widely expressed growth factor receptors,
it is implicated in playing an important role in the prolif-
eration of a wide variety of cell types in addition to the
previously studied cancerous cells [131]. For example, the
EGFR is ampliﬁed and overexpressed in tumors of epithelial
[131] and glial origins [132]a sw e l la so t h e rn u m e r o u s
neurometabolic-relatedtumorsobservedinhumans.Viruses
often associated with cancers, such as the hepatitis B virus,
which is associated with hepatocellular carcinoma, lead to
upregulation of EGFR signaling [133, 134]. Recent research
however has started to reveal a more widespread contribu-
tion of the EGFR to complex physiological processes such
as energy metabolism. In gastric cell lines, transactivation6 International Journal of Endocrinology
of the EGFR intimately involves leptin-signaling. Leptin is a
cytokine hormone secreted by adipocytes that regulates body
weight by decreasing food intake and energy expenditure
[135]. EGFR is also constitutively expressed in epithelium
and airway smooth muscle (ASM) [136]a sw e l la si nh e p a t o -
cytes [137]. The liver represents one of the most important
organs with respect to the global somatic control of both
energy expenditure and nutrient storage. Interestingly, it has
been reported that the EGFR demonstrate a 2-fold higher
expression in adult rat males compared to females and this
phenomenon may be inﬂuenced by secretory rhythm of
growth hormone (GH) in the pituitary [138].
Perinatal deletion of EGFR in hepatocytes results in
decreased body weight, whereas deletion in the adult liver
does not appear to aﬀect body mass. Although liver function
was not aﬀected, after partial hepatectomy, mice lacking
hepatic EGFR exhibit increased mortality and elevated
serum transaminases, indicative of liver damage. EGFR has
also been shown to be a critical regulator of hepatocyte
proliferation in the initial phases of liver regeneration
[139]. Several studies have investigated various regulatory
factors that contribute to the aﬃnity of EGF to EGFR in
rat hepatocytes, for example, thyroid hormones [140], age
[141], sex [141], fasting state [142], liver regeneration [143],
and an imposed experimental diabetic state [144–146]. In
accordance with this, a decreased hepatic EGFR expression
has been reported in diabetic mice [147, 148]. Given the
aforementioned molecular connectivity between the EGFR
and the insulin/IGF-1/GH signaling systems it is logical
that insulin may be one of the most important factors that
regulate EGFR gene expression in the liver [147]. EGF and
EGFR have been shown to be involved in an antiapoptotic
eﬀect in mouse hepatocytes [149] while EGF decreases the
glucose transporter 2 expression level in chicken hepatocytes
via PKC-MAPK [150]. Insulin deﬁciency causes a decrease
in EGFR and its mRNA gene expression: therapeutic intro-
duction of exogenous insulin restored the EGFR expression
to control levels [147]. In addition to the insulinotropic
regulation of hepatic EGFR function, the EGFR can be
tyrosine-phosphorylated in the liver in a time- and dose-
dependent manner in response to GH [151].
Carcinoembryonic antigen-related cell adhesion mole-
cule 1 (CEACAM1) is a cell adhesion protein and recently
identiﬁed a substrate of the EGFR [152]. Once phospho-
rylated by EGFR activation, CEACAM1 appears to mediate
increases in insulin sensitivity and can decrease insulin-
dependent mitogenesis in vivo.A na t t e n u a t e dr e s p o n s et o
insulin stimulation is causally related to obesity, type 2
diabetes, and metabolic syndrome, and improved whole-
bodyinsulinsensitivityisimportantinthetreatmentofthese
metabolic disorders [153]. CEACAM1 therefore appears to
play a central role in connecting EGFR activity with the
control of central obesity/insulin resistance. The connection
between EGFR activity and obesity is further reinforced
by the observation that obesity is strongly associated with
an increased mortality rate in cancer patients [154, 155].
The mechanism(s) linking altered metabolic pathways to
mitogenic activity may involve EGFR activation by fatty
acids independently of the cognate growth factor ligands of
EGFR [156, 157]. Free fatty acids (FFAs) are upregulated in
fasting plasma of obese individuals [158]. Rather than being
considered a passive organ adipose tissue is now appreciated
as a dynamic endocrine regulatory organ. In addition to
releasing FFAs [159] HB-EGF can be released from adipose
tissue in obese individuals into the portal circulation [160].
Both FFAs and HB-EGF possess the capacity to engender
EGFR activation in epithelial cells [152].
Aswehavediscussed,inadditiontoitsstrongroleinhep-
atic function, the EGFR also appears to coordinate multiple
aspectsoftheglucosemetabolic system.EGFRandthe EGFR
ligands, especially TGF-α, is functionally expressed in the
developing pancreas [161]. EGFR expression is essential for
normal pancreatic development and important in postnatal
β cellgrowth[162].Furthermore,EGFRsignaling isessential
for pancreatic islet β cell mass expansion during a high-fat
diet and pregnancy. In these scenarios cellular replication
appears to be the primary mechanism for the compensatory
β cell mass expansion [163]. EGFR signaling however was
not crucial to increase β cell proliferation after pancreatic
duct ligation, which serves as a model for islet neogenesis.
In EGFR-deﬁcient mice, the development of β cells occurs at
a later stage and the nascent β cells have a deﬁnite migratory
defect [162]. EGFR ligands, EGF, HB-EGF, and betacellulin
have all been implicated in β cell replication, diﬀerentiation
and lineage determination of developing islet cells [164–
167]. In addition to direct ligand-induced activation of the
pancreatic EGFR, local GPCR-mediated transactivation of
the receptor also appears to be potentially important in
the EGFR-mediated regulation of glucose metabolism [168].
Glucagon-like peptide 1 (GLP-1) is secreted by intestinal
L-cells in response to fat meals and carbohydrates [169–
171]. In addition to its direct roles in the alimentary canal,
for example, regulation of gastric emptying, GLP-1 also
can functionally regulate β cell function in the pancreas,
thereby providing another mechanism to control energy
metabolism. The GLP-1 peptide activates its cognate Class
B-type GLP-1 receptor to induce a c-Src-dependent EGFR
transactivation process. This signaling system involves a
proteolytic processing of membrane-anchored betacellulin,
or other EGF-like ligands, that results in a strong PI3-
kinase activation resulting in an eﬀective increase in β-cell
proliferation [172].
A common pathological aspect of metabolic aging is a
slow inevitable generation of global insulin resistance [13].
Insulin resistance and the associated metabolic syndrome
lead to a reduction in the ability of multiple cell types,
and especially neurons, to uptake glucose, regulate calcium
homeostasis and respond positively to trophic and neu-
rotrophic stimuli [173]. In addition to generating a global
disruption of neuronal energy balance, protracted insulin
resistance leads to a loss of vascular smooth muscle cell
(VSMC) functional regulation and promotion of VSMC
migration [174]. The latter is crucial in atherosclerotic devel-
opment and wound healing. Insulin has also been implicated
in epidermal wound healing though EGFR signaling [174].
Insulin can induce transactivation of EGFR by ADAM-
mediated HB-EGF-dependent process in VSMCs [174]. In
quiescent ﬁbroblasts, the mitogenic eﬀect of EGF requiresInternational Journal of Endocrinology 7
activation of the IGF-1R by circulating ligands including
IGF-I, IGF-II, or insulin [175]. As alterations in VSMC tone
and function are likely to aﬀect systemic hypertension, it
is interesting to note that elevated plasma glucose can also
result in the transactivation of the EGFR in renal disorders
[176].
6.EGFRandTrkBSignaling:Potential
Mediatorsof the Neurometabolic Interface
Considerable scientiﬁc progress has been made in studying
EGFR since Cohen and Carpenter’s publication (1975) that
EGF induces precocious eyelid opening in neonatal mice
[177]. The EGFR demonstrates an unprecedented number
of functional interactions with other receptors, ligands, and
moleculesotherthanitsowncognateligands.Understanding
these interactions is crucial to understanding the many
diﬀerent levels at which it is contributing to neurometabolic
processes. However, the placing of the EGFR in such a
centralandimportantroleinagingisoverlysimplistic.There
are of course likely to be other factors that also possess
a multidimensional impact upon neurometabolic function.
For example, the interaction of the EGFR with the metal ion
complexes leads to the resultant generation of downstream
signaling phenotypes which are more characteristic of that
engendered by the activation of the neurotrophic TrkB
signaling system. The activity of the neurotrophic receptor
family is already appreciated to be incredibly important
to the presence and generation of AD pathology [178].
Trk receptors are necessary for the survival, diﬀerentiation
and maturation of the developing brain [179]. Multiple
lines of evidence have demonstrated a reduction of brain-
derived neurotrophic factor (BDNF), the cognate ligand for
the TrkB receptor, in the brain of AD patients [180–183].
Furthermore, TrkB has been reported to be important for
LTP, a process considered to underpin memory function, in
hippocampal CA1 neurons [184, 185]. Both the TrkB and
EGFR signaling systems could potentially form a functional
link that generates a combined regulatory system deeply
associated with the majority of signaling systems controlling
the aging process. It is interesting to note that both the TrkB
and EGFR receptor systems can be directly linked through
GPCR “transactivation” signaling mechanisms. Therefore it
is likely that a “higher-order” synergy between TrkB and
the EGFR could account for a signiﬁcant component of
the neurometabolic aging phenotype. Also through their
common GPCR interaction in this “super-system” could be
easily targeted in a therapeutic manner as currently over
half of the eﬀective pharmacopeia is designed to employ
GPCR signaling systems. Such potential agents targeting
this EGFR-TrkB network may be able to exert tremendously
powerful therapeutic eﬀects in aging and neurodegenerative
paradigms.
7. Conclusion
In this paper we have attempted to uncover the context of
neuronal and metabolic interaction at the molecular level
during the aging process. Enormously complex systems
such as aging entail functional interaction of a myriad of
physiological and molecular signaling systems. To provide
a workable molecular framework on which to regulate and
controlsuchanenormoussystemitislikelythattheexistence
of factors that can bridge, and adapt to, a multiplicity of
signals, receptors, cell types, and tissues is crucial to the
orchestration of the overall network. It is at this level that
individual functional entities, such as the EGFR receptor
system, may come to prominence. In its ability to interact
and regulate multiple neuronal and metabolic functions
across lifespan, the EGFR may indeed be one of the most
important molecules whose enhanced study could yield
future insights of tremendous importance for gerontology.
In our paper we have drawn together evidence to aid the
appreciation of the truly multidimensional role of EGFR at
the systemic level in neurometabolic processes and in the
neurodegenerative trajectories seen in the aging process.
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